Effect of Dapagliflozin Treatment on Index of Cardiac Electrophysiological Balance in Patients With Heart Failure With Reduced Ejection Fraction
{{output}}
Background: Dapagliflozin (DAPA), a sodium-glucose cotransporter-2 (SGLT2) inhibitor, may attenuate the risk of ventricular arrhythmia (VA) through its antiarrhythmic properties in patients with heart failure with reduced ejectio... ...
